Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Crizotinib--latest champion in the cancer wars?

× No keyword cloud information.

19 in total

Review 1. ALK-immunoreactive neoplasms.

Authors: Parham Minoo; Huan-You Wang
Journal: Int J Clin Exp Pathol Date: 2012-05-23

2. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.

Authors: Jason N Rosenbaum; Ryan Bloom; Jason T Forys; Jeff Hiken; Jon R Armstrong; Julie Branson; Samantha McNulty; Priya D Velu; Kymberlie Pepin; Haley Abel; Catherine E Cottrell; John D Pfeifer; Shashikant Kulkarni; Ramaswamy Govindan; Eric Q Konnick; Christina M Lockwood; Eric J Duncavage
Journal: Mod Pathol Date: 2018-01-12 Impact factor: 7.842

Review 3. The genesis of tyrosine phosphorylation.

Authors: Tony Hunter
Journal: Cold Spring Harb Perspect Biol Date: 2014-05-01 Impact factor: 10.005

4. All-comers versus enrichment design strategy in phase II trials.

Authors: Sumithra J Mandrekar; Daniel J Sargent
Journal: J Thorac Oncol Date: 2011-04 Impact factor: 15.609

5. Inflammatory myofibroblastic tumor of the neck with thyroid invasion: a case report and literature review.

Authors: Jinlu Zhao; Duoji Han; Meizhuo Gao; Ming Liu; Chulei Feng; Gang Chen; Yue Gu; Ying Jiang
Journal: Gland Surg Date: 2020-08

6. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Authors: Apostolia-Maria Tsimberidou; Nancy G Iskander; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Rajyalakshmi Luthra; Yang Ye; Sijin Wen; Donald Berry; Razelle Kurzrock
Journal: Clin Cancer Res Date: 2012-09-10 Impact factor: 12.531

Crizotinib--latest champion in the cancer wars?

Review 1. ALK-immunoreactive neoplasms.

2. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.

Review 3. The genesis of tyrosine phosphorylation.

4. All-comers versus enrichment design strategy in phase II trials.

5. Inflammatory myofibroblastic tumor of the neck with thyroid invasion: a case report and literature review.

6. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Review 7. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

8. Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population.

Review 9. Drug repositioning for personalized medicine.

10. ALK and NSCLC: Targeted therapy with ALK inhibitors.